CagriSema导致平均体重下降23%, CagriSema caused 23% average weight loss but underperformed against Eli Lilly’s drug in a key trial.

诺沃·诺迪斯克(Novo Nordisk)的肥胖药物CagriSema(CagriSema)在一次试验中导致平均体重下降23%,但未能达到它的主要终点,根据REDEFINE 4研究的结果,与Eli Lilly的体重损失药物进行了头对头的比较,这低于Eli Lilly的体重损失药物。 Novo Nordisk’s obesity drug CagriSema led to 23% average weight loss in a trial but failed to meet its primary endpoint, falling short of Eli Lilly’s weight-loss drug in a head-to-head comparison, according to results from the REDEFINE 4 study. 结果标志着在争取有效治疗肥胖症的竞赛中出现倒退。 The outcome marks a setback in the competition for effective obesity treatments.